AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
AIM Vaccine Co., Ltd. has successfully completed Phase III clinical trials for its 13-valent pneumonia conjugate vaccine and obtained a production license, positioning the company to become a key supplier in a market with significant growth potential in China. The vaccine targets infants and young children and addresses an underserved global demand of 180 million doses, with China’s market projected to expand substantially by 2030.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.